BTX - Brooklyn ImmunoTherapeutics releases head and neck cancer phase 2 trial results

• A phase 2 trial of Brooklyn ImmunoTherapeutics' ( NASDAQ: BTX ) head and neck cancer candidate IRX-2 showed that the treatment tended to benefit patients more with later stage disease compared to those with earlier stages.
• The primary endpoint of the study was to estimate 2-year event-free survival (EFS). Secondary endpoints included overall survival and safety.
• Results showed that at two years of follow-up in the intention-to-treat population, median EFS was 48.3 months. Also, patients who received radiation only (no chemotherapy) as part of adjuvant therapy fared better than those who received both.
• Adverse events were higher in the treatment arm compared to the control arm.
• Brooklyn ImmunoTherapeutics ( BTX ) CEO Matt Angel said the results "provide a clear path forward for testing in patient populations that may benefit from treatment with IRX-2 in combination with checkpoint inhibitors."
• Brooklyn ImmunoTherapeutics ( BTX ), which is down ~89% year to date, is viewed as a strong sell by Seeking Alpha's Quant Rating .

For further details see: